Spinal Dural Arteriovenous Fistula International Data and Outcomes Registry

NCT07574645 | Recruiting

• 1 other identifier: SPIDER iRISID-2026-0174
• Study Type: observational
• Target: 1,000
• Locations: 1 country
• Sites: 1

Brief Summary

Given the lack of large multicenter datasets in the context of Spinal arteriovenous fistula, the strength of the evidence surrounding this rare disease is limited. SPIDER hence aims to address that by compiling patient-level data from centers all around the world.

Conditions

Spinal Dural Arteriovenous Fistula

Keywords

spinal dural arteriovenous fistula; spinal arteriovenous malformation; spinal AVF; sdAVF; international; multicenter; registry

Outcome Measures

Primary Outcomes (6)

• Treatment success

  Complete surgical/endovascular obliteration of the fistula

  Recorded at the end of the embolization or surgery.

• Recurrence

  Fistula recurrence

  Time-to-event Outcome Measures. Estimated period of time over which the event is assessed: on average 1.5 years after surgery.

• Status of symptoms at last clinical follow-up

  Improved, unchanged, or worsened pain, sensory, and motor symptoms

  Time-to-event Outcome Measures. Estimated period of time over which the event is assessed: on average 1.5 years after surgery.

• Modified Aminoff-Logue Scale

  Gait and bowel/bladder score

  Time-to-event Outcome Measures. Estimated period of time over which the event is assessed: on average 1.5 years after surgery.

• Modified Rankin Scale

  Measure of functional independence

  Time-to-event Outcome Measures. Estimated period of time over which the event is assessed: on average 1.5 years after surgery.

• Mortality

  Time-to-event Outcome Measures. Estimated period of time over which the event is assessed: on average 1.5 years after surgery.

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The registry will include patients from 40 different hospitals in 20 different countries.

You may qualify if:

• Type 1 spinal dural arteriovenous fistula, confirmed on imaging
• Surgically or endovascularly treated
• At least 1 available primary outcome

Sponsors & Collaborators

• Thomas Jefferson University: lead

Study Sites (1)

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19102, United States

RECRUITING

Central Study Contacts

Pascal Jabbour, MD

CONTACT

215-955-7000; pascal.jabbour@jefferson.edu

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: The Angela and Richard T. Clark Distinguished Professor of Neurological Surgery and Radiology; Division Chief of Neurovascular Surgery & Endovascular Neurosurgery

Study Record Dates

• First Submitted: April 22, 2026
• First Posted: May 8, 2026
• Study Start: January 5, 2026
• Primary Completion: May 1, 2026
• Study Completion: May 1, 2026
• Last Updated: May 8, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)